Patents by Inventor Mark Andrew MERCHANT

Mark Andrew MERCHANT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230321102
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. GDC-6036) and an PI3K-inhibitor (e.g. inavolisib) and methods of using such combination therapies.
    Type: Application
    Filed: April 4, 2023
    Publication date: October 12, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Zhen SHI, Chunyan SONG, Neekesh Vijay DHARIA, Stephanie Royer JOO
  • Publication number: 20220193077
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1) and an EGFR-inhibitor and methods of using such combination therapies.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 23, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie Anne EVANGELISTA, Stephanie Royer JOO, Ting-Kun Mark LIN, Sandhya Vinayak MANDLEKAR, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN
  • Publication number: 20220152030
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.
    Type: Application
    Filed: November 11, 2021
    Publication date: May 19, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie Evangelista, Mark Andrew Merchant, Jennifer Lee Schutzman, Ting-Kun Mark Lin, Stephanie Royer Joo, Sandhya Vinayak Mandlekar, Stuart G. Lutzker
  • Publication number: 20220152029
    Abstract: Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).
    Type: Application
    Filed: November 11, 2021
    Publication date: May 19, 2022
    Applicant: Genentech, Inc.
    Inventors: Marie EVANGELISTA, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Ting-Kun Mark LIN, Stephanie Royer JOO, Sandhya Vinayak MANDLEKAR